- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such ...

Progressive supranuclear palsy (PSP) is a rare, degenerative neurological condition. It usually starts in middle age and can cause symptoms similar to those of Parkinson’s disease. PSP can cause ...

After 48 weeks of treatment, TPN-101 reduced the levels of neurofilament light chain and interleukin 6, both key biomarkers of neurodegeneration and neuroinflammation in PSP. The Food and Drug ...

The International PSP Research and Treatment Center (the "Center") will integrate the infrastructure and expertise of the three parties to execute a comprehensive array of functions, including ...

The market size of the progressive supranuclear palsy treatment market is expected to experience significant growth in the coming years, as more research is conducted on the disease and new treatments ...

The centre will facilitate treatment, research, and the potential commercialisation of PSP therapies. Seoul National University Bundang Hospital (SNUBH), along with CurePSP, Inc. and GemVax & KAEL Co.